Aerovance
Berkeley
About Aerovance
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovant™, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aeroderm™, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $152.5M
- Last round: Series Unknown (Mar 2011)
- Website: aerovance.com
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/aerovance-2756891 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.